We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORCL icon
151
Oracle
ORCL
$432B
$28.1K ﹤0.01%
191
-12
-6% -$1.95K
DGX icon
152
Quest Diagnostics
DGX
$25.9B
$25.7K ﹤0.01%
131
-7,149
-98% -$1.39M
QCOM icon
153
Qualcomm
QCOM
$173B
$25.4K ﹤0.01%
197
-12
-6% -$1.75K
RXRX icon
154
Recursion Pharmaceuticals
RXRX
$1.71B
$14.2K ﹤0.01%
4,627
-294
-6% -$1.14K
QGEN icon
155
Qiagen
QGEN
$8.85B
$9.73K ﹤0.01%
+243
New +$11.5K
AMRX icon
156
Amneal Pharmaceuticals
AMRX
$6.18B
– –
-7,913
Closed -$99.7K
ANET icon
157
Arista Networks
ANET
$252B
– –
-4,800
Closed -$629K
APLS
158
DELISTED
Apellis Pharmaceuticals
APLS
– –
-4,210
Closed -$106K
AVTR icon
159
Avantor
AVTR
$9.26B
– –
-276,266
Closed -$3.17M
AZN icon
160
AstraZeneca
AZN
$242B
– –
-15,216
Closed -$2.8M
BEAM icon
161
Beam Therapeutics
BEAM
$2.73B
– –
-111,510
Closed -$3.09M
BKD icon
162
Brookdale Senior Living
BKD
$3.02B
– –
-167,444
Closed -$1.81M
BMRN icon
163
BioMarin Pharmaceuticals
BMRN
$13.1B
– –
-65,008
Closed -$3.86M
CDNA icon
164
CareDx
CDNA
$2.35B
– –
-431,070
Closed -$8.12M
CGON icon
165
CG Oncology
CGON
$6.66B
– –
-3,095
Closed -$129K
CMPS
166
Compass Pathways
CMPS
$1.83B
– –
-142,243
Closed -$981K
CORT icon
167
Corcept Therapeutics
CORT
$12.4B
– –
-10,495
Closed -$365K
DOCS icon
168
Doximity
DOCS
$4.46B
– –
-11,817
Closed -$523K
EXAS
169
DELISTED
Exact Sciences
EXAS
– –
-16,062
Closed -$1.63M
EXEL icon
170
Exelixis
EXEL
$12.6B
– –
-7,361
Closed -$323K
FOLD
171
DELISTED
Amicus Therapeutics
FOLD
– –
-10,735,195
Closed -$153M
GH icon
172
Guardant Health
GH
$21.1B
– –
-3,004
Closed -$307K
GMAB icon
173
Genmab
GMAB
$19.6B
– –
-3,009
Closed -$92.7K
ICLR icon
174
Icon
ICLR
$12.6B
– –
-24,560
Closed -$4.48M
IDYA icon
175
IDEAYA Biosciences
IDYA
$3.5B
– –
-4,942
Closed -$171K
4 5 6
7
8

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.